Events

Microgenics CEDIA Tobramycin II Assay 의 리콜

New Zealand Medicines and Medical Devices Safety Authority에 따르면, 해당 리콜 는 New Zealand 에서 Microgenics Corporation 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    15590
  • 사례 시작날짜
    2013-10-29
  • 사례 국가
    New Zealand
  • 사례 출처
    NZMMDSA
  • 사례 출처 URL
    https://medsafe.govt.nz/hot/Recalls/RecallSearch.asp
  • 비고 / 경고
    Data from New Zealand is current through July 2018. All of the data comes from the New Zealand Medicines and Medical Devices Safety Authority, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and New Zealand.
  • 데이터 추가 비고
    Recalling Organisation: Beckman Coulter NZ Ltd, Suite 2, Level 4, 30 St Benedicts Street, Newton, AUCKLAND
  • 원인
    In-house testing of the cedia® tobramycin ii assay (ln: 60169764) shows that the reconstituted reagents do not maintain 30 days reconstituted stability. the instability of the reconstituted reagents may cause higher recovery of samples. hence, lot number 60169764 reagents must be used within 14 days after reconstitution. reconstituted reagents beyond the 14 days should be discontinued and discarded.
  • 조치
    Instructions for use to be updated

Device

Microgenics CEDIA Tobramycin II Assay
  • 모델명 / 제조번호(시리얼번호)
    Model: Catalogue Number: A96842, Affected: Lot: 60169764
  • Manufacturer
    Microgenics Corporation

Manufacturer

Microgenics Corporation